


# Comprehensive Testing for Thrombotic Microangiopathy



Cincinnati Children's Hospital Medical Center is the only center in the United States performing a full array of molecular and cellular diagnostic testing for thrombotic microangiopathies (TMA), including atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP), rare but serious medical conditions that can be fatal if not treated.

## WHY TEST AT CINCINNATI CHILDREN'S?

- In addition to being the only comprehensive testing center for TMA in the United States, Cincinnati Children's is one of only two facilities in the nation that offers genetic testing for TMA.
- Comprehensive testing at a single location can expedite early definitive diagnosis, which is critical for beginning timely treatment.
- We test both children and adults. While slightly more common in children, TMA can affect children and adults of all ages.
- As the leading research lab for TMA, we continue to advance testing to provide new ways to diagnose TMA, and to make discoveries about the diseases that may contribute to enhanced treatment options.

## CUSTOMIZED TESTING RESULTS

The final interpretation explains the clinical significance of test results, and provides recommendations for any additional warranted testing and clinical management. Genetic counseling interpretation is included in the written report.

## TREATMENT APPROACH

Board-certified pediatric nephrologists, hematologists, molecular geneticists and genetic counselors are available for telephone or email consultations regarding test selection, clinical interpretation, medical management and follow-up testing, genetic counseling and additional studies of at-risk family members.

## EASY-TO-ORDER DIAGNOSTIC TESTING

At Cincinnati Children's all TMA testing is conducted by a single lab resource with a single point of contact and a single location to send specimens—eliminating the need to coordinate multiple testing sites.




Cincinnati Children's is ranked #6 in Nephrology and #3 in the nation among Honor Roll hospitals.

## CONTACT US

To order testing, complete the TMA test requisition found online at:  
[www.cincinnatichildrens.org/tma](http://www.cincinnatichildrens.org/tma)

Phone: 513-636-4530




## QUICK TURNAROUND

Critical results of individual tests are provided as soon as available.

ADAMTS13	TAT / Performed
Activity	24 hrs/daily
Inhibition Test	24 hrs/daily
Antibody Quant	48 hrs
ADAMTS13 Panel (Activity, Inhibition Test, Antibody Quant)	24 hrs/daily
Gene Sequencing	4 wks
Other Tests	TAT / Performed
aHUS Genetic Susceptibility Panel	Up to 12 wks
Any Single Gene Sequencing Test	Up to 12 wks
Targeted mutation analysis	4 wks
C3 Level	24 hrs/daily
C4 Level	24 hrs/daily
CH50	24 hrs/M, W, F
Factor B Level	72 hrs/M, F
Bb	1 wk
Factor H	72 hrs/M, F
Factor H Auto-Antibody	24 hrs/M, TH—stat available
Factor I	72 hrs/M, F
MCP/CD46 Flow Cytometry	24 hrs/daily
SC5b-9 (MAC Complex)	2 wks

## THROMBOTIC MICROANGIOPATHY TESTING ALGORITHM



\* aHUS can still be made as a diagnosis with completely normal genetic testing because all contributing genetic factors are not yet known. Both patients with and without mutations seem to have the same response to eculizumab.

For more information, contact us at 513-636-4530.

[www.cincinnatichildrens.org/tma](http://www.cincinnatichildrens.org/tma)